Lomustine (CCNU): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Toxicological Profile

Executive Summary

Lomustine, also known by the abbreviation CCNU, is a potent, small-molecule chemotherapeutic agent belonging to the nitrosourea class of alkylating drugs. First approved in 1976, it has a long and established history in the treatment of specific malignancies. The defining physicochemical characteristic of Lomustine is its high lipophilicity, a property that facilitates its passage across the blood-brain barrier. This unique distribution profile has established Lomustine as a cornerstone therapy for central nervous system (CNS) cancers, particularly primary and metastatic brain tumors such as glioblastoma, and as a second-line agent for refractory Hodgkin's lymphoma.[1]

The therapeutic utility of Lomustine is fundamentally intertwined with its significant and challenging toxicological profile. As a cell-cycle non-specific agent, it exerts its cytotoxic effects by inducing lethal damage to the DNA of cancer cells. However, this same mechanism affects rapidly dividing healthy cells, leading to a predictable and severe pattern of toxicity. The principal and dose-limiting toxicity is a profound, delayed, and cumulative myelosuppression, which manifests as leukopenia and thrombocytopenia. The nadir of this effect occurs 4 to 6 weeks post-administration, a pharmacokinetic reality that dictates the drug's unique and mandatory single-dose, 6-week treatment cycle to allow for bone marrow recovery.[4]

Beyond hematologic effects, Lomustine is associated with significant organ toxicities, including dose-related pulmonary fibrosis, nephrotoxicity, and hepatotoxicity, which require diligent patient monitoring.[7] Furthermore, its DNA-damaging mechanism carries an inherent long-term risk of inducing secondary malignancies, such as acute leukemia and myelodysplasia.[7] The report details the drug's journey from its original marketing as CeeNU by Bristol-Myers Squibb to its current status as a single-source, high-cost medication branded Gleostine by NextSource Biotechnology. This transition has had profound implications for patient access, financial toxicity, and the landscape of clinical research in neuro-oncology, where Lomustine remains a critical comparator agent.[10] This monograph provides an exhaustive analysis of Lomustine, integrating its chemical properties, molecular pharmacology, clinical applications, and complex safety considerations to offer a comprehensive resource for clinicians and researchers.

Chemical Identity and Physicochemical Properties

The precise identification and understanding of Lomustine's physicochemical properties are essential for appreciating its formulation, biological activity, and clinical niche.

Systematic Nomenclature and Identifiers

Lomustine is identified by a range of chemical and regulatory codes that ensure its unambiguous characterization across scientific and clinical domains.

• Common Names: Lomustine, CCNU [2]
• Brand Names: Gleostine, CeeNU (original), Belustine, Cecenu, Citostal [2]
• DrugBank ID: DB01206 [15]
• CAS Registry Number: 13010-47-4 [11]
• IUPAC Name: 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [11]
• Chemical Identifiers:
• InChI: InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14) [11]
• InChIKey: GQYIWUVLTXOXAJ-UHFFFAOYSA-N [11]
• SMILES: C1CCC(CC1)NC(=O)N(CCCl)N=O [11]
• Other Database Identifiers: ChEBI (6520), National Cancer Institute (NCI) Thesaurus Code (C617), NSC Code (79037), UNII (7BRF0Z81KG) [11]

Molecular Formula and Weight

The elemental composition and mass of the Lomustine molecule are precisely defined.

• Molecular Formula: C9​H16​ClN3​O2​ [11]
• Molecular Weight: The average molecular weight is approximately 233.70 g/mol, with a monoisotopic mass of 233.093104478 Da.[2]

Physical and Chemical Properties

Lomustine's physical characteristics are critical determinants of its pharmacokinetic behavior and handling requirements.

• Appearance: It is a solid, typically described as a pale yellow powder.[5]
• Melting Point: The melting point is consistently reported in the range of 88–90 °C.[11]
• Solubility Profile: The solubility profile of Lomustine is a defining feature. It is highly lipid-soluble (lipophilic) and, conversely, relatively insoluble in aqueous solutions. Its solubility in water is less than 0.05 mg/mL.[2] In contrast, it is soluble in 10% ethanol (0.05 mg/mL), highly soluble in absolute ethanol (70 mg/mL), and freely soluble in organic solvents such as chloroform and acetone.[5] This high lipophilicity is quantified by its octanol-water partition coefficient (LogP), which is approximately 2.83, indicating a strong preference for lipid environments.[11]
• Stability and Storage: Lomustine is sensitive to heat and should be stored at room temperature, protected from moisture and direct light.[1] For long-term chemical stability, some suppliers recommend frozen storage (<0 °C).[18] Due to its cytotoxic and hazardous nature, it is classified as a dangerous good for transport and requires special handling procedures.[18] Under fire conditions, it can decompose to form hazardous products, including carbon oxides, nitrogen oxides, and hydrogen chloride gas.[11]

Structural Analysis

The chemical structure of Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, is composed of distinct functional groups that dictate its pharmacological properties. The molecule can be deconstructed into two key components:

1. The Cytotoxic Moiety: The (2-chloroethyl)nitrosourea group is the reactive portion of the molecule. This functional group is common to the nitrosourea class of chemotherapeutics and is the source of the reactive intermediates responsible for both alkylating nucleic acids and carbamoylating proteins.[2]
2. The Lipophilic Moiety: The cyclohexyl group is a non-polar, saturated hydrocarbon ring. Its presence confers the high degree of lipid solubility that is the hallmark of Lomustine.[11]

The architecture of the Lomustine molecule is a clear example of rational drug design, where chemical structure directly predicts clinical function. The high lipophilicity imparted by the cyclohexyl group is not merely an incidental property; it is the key that unlocks the drug's primary clinical application. This fat-solubility allows Lomustine to readily diffuse across the tightly regulated lipid bilayer of the blood-brain barrier (BBB), a physiological obstacle that prevents most systemic chemotherapies from reaching the CNS.[2] Consequently, the cyclohexyl group functions as a delivery vehicle, transporting the cytotoxic (2-chloroethyl)nitrosourea "warhead" to its intended target site within the brain. This intrinsic ability to penetrate the CNS directly explains why Lomustine's primary FDA-approved indications include primary and metastatic brain tumors, malignancies that are notoriously difficult to treat with conventional systemic agents.[1]

Table 1: Lomustine Identifiers and Physicochemical Properties
Common Name	Lomustine, CCNU
DrugBank ID	DB01206
Type	Small Molecule
CAS Number	13010-47-4
IUPAC Name	1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
Molecular Formula	C9​H16​ClN3​O2​
Average Molecular Weight	233.70 g/mol
Physical Appearance	Pale yellow powder/solid
Melting Point	88–90 °C
Solubility	Water: <0.05 mg/mL; Absolute Ethanol: 70 mg/mL; Freely soluble in chloroform/acetone
LogP	~2.83
SMILES	C1CCC(CC1)NC(=O)N(CCCl)N=O
	2

Molecular and Cellular Pharmacology

Lomustine's anticancer activity stems from its ability to induce catastrophic damage to the fundamental machinery of cancer cells. Its mechanism is multifaceted and potent, leading to cell death but also contributing to its significant toxicity.

Classification

Lomustine is pharmacologically classified as a bifunctional, cell-cycle non-specific antineoplastic agent.[2] It belongs to the nitrosourea family of alkylating agents.[1] Its cell-cycle non-specific nature means it can exert its cytotoxic effects on cancer cells at any stage of the cell division cycle, which contributes to its broad activity against various tumor types.[2]

Mechanism of Action - A Dual Cytotoxic Attack

Lomustine itself is an inactive prodrug. Following administration, it undergoes spontaneous, non-enzymatic hydrolysis and extensive hepatic metabolism to generate highly reactive intermediates that are responsible for its cytotoxic effects.[15] These intermediates launch a two-pronged assault on the cancer cell:

1. Alkylation and Cross-Linking of Nucleic Acids: This is the principal and most critical mechanism of action. One of the reactive metabolites is a chloroethyl carbonium ion, which is a powerful electrophile. This ion covalently attaches (alkylates) to nucleophilic sites on the bases of both DNA and RNA.[2] The primary and most therapeutically relevant target for this alkylation is the O6 position of the guanine base in DNA.[2] Initially, this creates a monofunctional adduct. This adduct can then undergo a secondary reaction, leading to the formation of a highly lethal DNA lesion known as an interstrand cross-link (ICL).[2] An ICL physically tethers the two strands of the DNA double helix together, making it impossible for them to separate. This blockage of strand separation effectively halts essential cellular processes, including DNA replication and transcription, which are prerequisites for cell division and survival. The accumulation of this irreparable damage ultimately triggers the cell's intrinsic suicide program, known as apoptosis.[2]
2. Carbamoylation of Proteins: A second reactive intermediate, an isocyanate, is also formed during Lomustine's breakdown. This molecule can react with the epsilon-amino group of lysine residues on various cellular proteins, a process known as carbamoylation.[2] This modification can inactivate several key enzymes. Notably, this includes enzymes involved in the cell's defense and repair systems, such as glutathione reductase and certain DNA repair proteins. By inhibiting these enzymes, carbamoylation disrupts the cell's ability to manage oxidative stress and repair the very DNA damage being inflicted by the alkylating metabolite. This action also interferes with RNA processing, further contributing to cellular dysfunction.[13]

This dual mechanism represents a powerful synergy of destruction. The alkylation component delivers a direct, potent blow to the cell's genetic blueprint. Simultaneously, the carbamoylation component acts as a saboteur, disabling the cell's repair crews and defense systems. This "one-two punch" ensures that the DNA damage is not only inflicted but is also more likely to be permanent and lethal. This synergistic action helps to explain the high potency of Lomustine and its effectiveness even in some tumors that have developed resistance to other alkylating agents that rely on a single mode of action.

Resistance Mechanisms

The primary mechanism of cellular resistance to Lomustine and other nitrosoureas involves the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). MGMT is a "suicide enzyme" that can directly remove the alkyl adduct from the O6 position of guanine, transferring it to one of its own cysteine residues and becoming inactivated in the process.[27] If this repair occurs before the adduct can form a lethal interstrand cross-link, the cell can survive. Therefore, tumors with high levels of MGMT expression are often resistant to Lomustine, making MGMT status a critical prognostic and predictive biomarker, especially in the treatment of gliomas.[28] While nitrosoureas generally do not share cross-resistance with other classes of alkylating agents, a degree of cross-resistance between Lomustine and its close relative, carmustine (BCNU), has been observed, likely due to their similar mechanisms of action and resistance.[7]

The pharmacology of Lomustine reveals a direct and unbroken causal chain that connects its therapeutic benefit to its toxic liabilities. The very mechanism that makes it an effective anticancer drug—the induction of widespread DNA damage—is also the direct cause of its most significant adverse effects. This non-specific damage affects not only rapidly dividing cancer cells but also healthy, rapidly proliferating host cells, such as hematopoietic stem cells in the bone marrow. This leads directly to the drug's most common and dose-limiting toxicity: myelosuppression.[1] Furthermore, DNA damage is the fundamental basis of mutagenesis. Lomustine is known to be clastogenic (causing chromosomal breaks) and can cause genetic defects.[4] When this sublethal DNA damage occurs in a surviving stem cell and is repaired incorrectly, it can lead to mutations that drive malignant transformation. This explains why Lomustine is carcinogenic in animal models and why long-term therapy in humans is associated with a significant risk of developing secondary malignancies, such as acute leukemia and myelodysplasia.[4] Thus, the drug's action as a therapeutic, a toxin, and a carcinogen all originate from the same fundamental molecular event: the alkylation of DNA.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Lomustine is characterized by rapid absorption, extensive metabolism into active compounds with long half-lives, and excellent penetration into the central nervous system. This profile is central to understanding both its clinical efficacy and its unique toxicity pattern.

Absorption

Lomustine is administered orally in capsule form. It is rapidly and completely absorbed from the gastrointestinal tract, with absorption occurring within 30 to 60 minutes of ingestion.[7] To mitigate the common side effects of nausea and vomiting, it is often recommended that patients take the medication on an empty stomach, typically at bedtime.[1]

Distribution

• Lipophilicity and Tissue Penetration: As a highly lipophilic compound, Lomustine is widely and rapidly distributed throughout the body's tissues following absorption.[4]
• Blood-Brain Barrier (BBB) Penetration: The most clinically significant feature of Lomustine's distribution is its ability to readily cross the blood-brain barrier.[2] Studies have shown that concentrations of the drug's metabolites in the cerebrospinal fluid (CSF) can reach 50% or more of the levels measured concurrently in the plasma.[4] This effective CNS penetration is what makes Lomustine a valuable agent for treating brain tumors.
• Plasma Protein Binding: Approximately 50% of the drug in circulation is bound to plasma proteins.[2]

Metabolism

• Prodrug Activation and First-Pass Effect: Lomustine functions as a prodrug. It undergoes extensive and rapid metabolism immediately after absorption, primarily in the liver via the cytochrome P450 (CYP450) microsomal enzyme system.[13] This first-pass metabolism is so complete that the intact parent drug is often undetectable in plasma samples following oral administration.[30]
• Active Metabolites: The biotransformation of Lomustine yields several active metabolites that are responsible for the drug's therapeutic and toxic effects. The principal active metabolites are two monohydroxylated isomers: trans-4-hydroxylomustine (trans-4) and cis-4-hydroxylomustine (cis-4).[30] Clinical studies show that the trans-isomer is generally the major metabolite found in plasma, with a trans-to-cis ratio of approximately 6:4.[30] These hydroxylated metabolites are believed to possess enhanced alkylating activity and may have a better therapeutic index (ratio of efficacy to toxicity) than the parent compound.[31]
• Enzymes Involved: While comprehensive human studies are limited, in-vitro data and animal studies suggest that the metabolism of Lomustine involves several CYP450 isoenzymes, most notably CYP3A4, CYP2D6, and CYP2C19.[7]

Excretion

The elimination of Lomustine and its metabolites occurs predominantly through the kidneys. Following an oral dose of radio-labeled Lomustine, approximately 50% of the radioactivity is excreted in the urine as degradation products within the first 24 hours.[5] A very small fraction, less than 5%, is eliminated in the feces.[7]

Half-Life

The clinical pharmacology of Lomustine is dictated not by the parent drug, but by its metabolites. The parent compound has a very short plasma half-life of approximately 94 minutes and is often cleared so rapidly that it cannot be measured.[15] In stark contrast, the active hydroxylated metabolites exhibit a much longer serum half-life, ranging from

16 to 48 hours.[7]

This pharmacokinetic profile, specifically the long half-life of the active metabolites, is the single most important factor governing the clinical use and toxicity of Lomustine. The parent drug acts as a delivery vehicle that is rapidly absorbed and converted into its active forms. These metabolites then persist in the body for 1 to 2 days, exerting a sustained cytotoxic effect. This prolonged exposure is what drives the profound and characteristically delayed myelosuppression. The hematopoietic stem cells in the bone marrow are continuously assaulted for days after the single oral dose, and the full impact on blood cell counts—the nadir—is not seen until 4 to 6 weeks later.[4] Consequently, the rigid 6-week dosing interval is not an arbitrary schedule but a mandatory clinical adaptation to allow the bone marrow sufficient time to recover from this sustained toxic insult before the next dose is administered. The entire framework for the safe clinical management of Lomustine is built upon this fundamental pharmacokinetic principle.

Clinical Applications and Therapeutic Regimens

Lomustine has maintained a specific and important role in oncology for decades, primarily due to its ability to treat cancers within the central nervous system. Its use is guided by specific indications, dosing schedules, and stringent monitoring requirements.

FDA-Approved Indications (Human Medicine)

The U.S. Food and Drug Administration (FDA) has approved Lomustine for the following indications:

• Brain Tumors: Lomustine is indicated as palliative therapy for both primary brain tumors (e.g., glioblastoma, anaplastic astrocytoma, other malignant gliomas) and metastatic brain tumors. It is typically used as a single agent or in combination regimens for patients who have already undergone appropriate surgical and/or radiotherapeutic procedures.[1] Following its approval in 1976, it served as a standard of care for high-grade gliomas for many years.[2]
• Hodgkin's Lymphoma: Lomustine is indicated as a second-line therapy for patients with Hodgkin's lymphoma whose disease has progressed or relapsed following treatment with initial chemotherapy regimens. In this setting, it is generally used as a component of combination chemotherapy.[1]

Off-Label and Investigational Uses

Beyond its approved indications, Lomustine has been utilized in the treatment of other malignancies, often in refractory settings after conventional therapies have failed. These off-label uses have included various solid tumors such as lung cancer, malignant melanoma, breast cancer, and cancers of the gastrointestinal tract.[2]

Reflecting its established activity in neuro-oncology, Lomustine frequently serves as a standard-of-care comparator or control arm in clinical trials evaluating novel agents for brain tumors. For example, completed Phase 2 trials have investigated Lomustine in combination with drugs like axitinib and regorafenib for the treatment of recurrent glioblastoma multiforme (GBM).[38] It is also being studied in trials for patients with specific biomarkers, such as APC loss or CTNNB1 mutations.[39]

Veterinary Medicine

Lomustine is widely used as an "off-label" chemotherapeutic agent in veterinary oncology, particularly for dogs and cats. It has demonstrated success in treating conditions such as resistant or relapsed lymphomas (especially cutaneous T-cell lymphoma, where it can be a first-line agent), mast cell tumors, brain tumors, and histiocytic sarcomas.[2] Its administration and side effect profile in animals parallel those seen in humans, with myelosuppression and potential organ toxicities being primary concerns.[2]

Administration and Dosing

• Route of Administration: Lomustine is administered orally as capsules.[1]
• Standard Dosing: The recommended dose for both adult and pediatric patients is 130 mg/m² of body surface area, given as a single oral dose once every 6 weeks.[1]
• Dose Formulation: The total prescribed dose is achieved by combining capsules of different strengths and colors. Available capsule strengths are 5 mg (yellow), 10 mg (white), 40 mg (white and green), and 100 mg (green).[2] The final dose is typically rounded to the nearest 5 mg to accommodate these strengths.[37]
• Patient Instructions: It is critical that patients understand they must take all capsules provided for a single dose at the same time.[1] To minimize gastrointestinal upset, the dose is best taken on an empty stomach (at least 2 hours before or 1 hour after eating), often at bedtime.[1]

Dosage Modifications and Monitoring

Safe administration of Lomustine is critically dependent on careful monitoring and appropriate dose adjustments based on toxicity.

• Hematologic Monitoring: The cornerstone of management is weekly monitoring of complete blood counts (CBC) for at least 6 weeks following each dose to track the nadir and recovery of leukocytes and platelets.[4] A subsequent course of Lomustine should not be administered until the leukocyte count has recovered to greater than 4,000/mm³ and the platelet count has recovered to greater than 100,000/mm³.[4]
• Dose Adjustment for Myelosuppression: The dose for the next cycle is adjusted based on the hematologic nadir observed from the prior cycle, as detailed in Table 2.
• Dose for Compromised Marrow: For patients with pre-existing bone marrow compromise (e.g., from prior chemotherapy or radiation), a reduced starting dose of 100 mg/m² every 6 weeks is recommended.[37]
• Renal Impairment: Dose reduction is required for patients with impaired kidney function. Guidelines suggest administering 75% of the standard dose for a creatinine clearance (CrCl) of 10-50 mL/min and 25-50% of the dose for a CrCl <10 mL/min.[22]
• Hepatic Impairment: While no specific dosage guidelines exist, Lomustine is metabolized by the liver. Therefore, patients with hepatic impairment should be monitored closely, with dose adjustments based primarily on the degree of hematologic toxicity observed.[7]

Table 2: Recommended Dosage Adjustments for Lomustine Based on Hematologic Nadir
Nadir Leukocytes (/mm³)	Nadir Platelets (/mm³)	Percentage of Prior Dose to Administer
≥3,000	≥75,000	100%
2,000 – 2,999	25,000 – 74,999	70%
<2,000	<25,000	50%
	5

Comprehensive Safety and Toxicology Profile

The therapeutic use of Lomustine is inseparable from its significant toxicological risks. Its potent, non-selective mechanism of action leads to a range of adverse effects, from predictable and manageable side effects to severe, life-threatening, and long-term toxicities.

FDA Boxed Warnings

The U.S. FDA mandates two critical boxed warnings on the prescribing information for Lomustine, highlighting its most severe risks:

• Delayed Myelosuppression: This is the most common, most severe, and dose-limiting toxicity of Lomustine. The drug causes a profound suppression of the bone marrow that is characteristically delayed, dose-related, and cumulative. This can lead to fatal bleeding (from thrombocytopenia) and overwhelming infections (from leukopenia). The lowest point (nadir) of platelet counts typically occurs about 4 weeks after a dose, while the leukocyte nadir occurs at 5 to 6 weeks. The suppression can persist for 1 to 2 weeks or longer. Because the toxicity is cumulative, subsequent doses can lead to more severe and prolonged cytopenias. This risk mandates that blood counts be monitored weekly for a minimum of 6 weeks after each dose and that treatment cycles are spaced at least 6 weeks apart.[5]
• Risk of Overdosage: Accidental overdose of Lomustine can be fatal. The most common medication error is inadvertent daily administration instead of the correct once-every-6-weeks schedule. To mitigate this risk, the FDA warns that prescribers should only write prescriptions for a single dose at a time, and pharmacists should dispense only the exact number of capsules required for that single dose. Both clinicians must emphatically counsel the patient on the correct 6-week dosing interval.[5] Symptoms of overdose include severe bone marrow suppression, abdominal pain, diarrhea, vomiting, lethargy, and dizziness.[6]

Hematologic Toxicity

As highlighted in the boxed warning, myelosuppression is the principal toxicity. Thrombocytopenia (low platelet count) is generally more severe than leukopenia (low white blood cell count), and both can be dose-limiting.[4] Anemia (low red blood cell count) also occurs but is typically less frequent and less severe.[4] Patients are at high risk for bleeding (bruising, petechiae, bloody stools) and infections (fever, chills, sore throat) during the nadir period and must be counseled on precautions.[1]

Organ-Specific Toxicities

• Pulmonary Toxicity: Lomustine can cause serious and potentially fatal lung damage, manifesting as pulmonary infiltrates and/or fibrosis. The risk is dose-related and increases significantly with cumulative doses exceeding 1,100 mg/m², although it has been reported at lower doses. The onset is often insidious and can be delayed, occurring 6 months or even up to 15-17 years after the initiation of therapy. Patients with a baseline forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) below 70% of predicted are at particularly high risk. Baseline and frequent periodic pulmonary function tests (PFTs) are required. If pulmonary fibrosis is diagnosed, Lomustine must be permanently discontinued.[4]
• Nephrotoxicity (Kidney Damage): Prolonged therapy with large cumulative doses of Lomustine can lead to kidney damage. This may present as progressive azotemia (elevated nitrogenous waste in the blood), a decrease in kidney size, and ultimately, renal failure. Renal function tests should be monitored periodically throughout treatment.[1]
• Hepatotoxicity (Liver Damage): A reversible type of liver toxicity has been reported in a small percentage of patients. This is typically manifested by transient elevations in liver function tests, including transaminases (AST/ALT), alkaline phosphatase, and bilirubin. Periodic monitoring of liver function is recommended.[4]

Carcinogenesis, Mutagenesis, and Teratogenicity

• Secondary Malignancies: The DNA-damaging nature of Lomustine carries an inherent risk of carcinogenesis. Long-term therapy with nitrosoureas is associated with the development of secondary cancers, most notably acute leukemia and myelodysplastic syndromes (MDS).[4] This represents a devastating late effect of the therapy itself.
• Mutagenicity and Teratogenicity: Lomustine is mutagenic and has been shown to be clastogenic, meaning it can cause breaks in chromosomes.[4] Animal studies have demonstrated that it is embryotoxic and teratogenic, causing fetal harm at doses equivalent to those used in humans. For this reason, it is classified as FDA Pregnancy Category D and is not recommended for use in pregnant women.[2]

Other Common and Serious Adverse Events

• Gastrointestinal Toxicity: Nausea and vomiting are very common, typically occurring 3 to 6 hours after a dose and usually resolving within 24 hours. The prophylactic use of antiemetic medications is strongly recommended. Other GI effects include anorexia (loss of appetite), which may last for several days, stomatitis (sores in the mouth), and diarrhea.[1]
• Neurological Reactions: Some patients may experience neurological side effects, including disorientation, lethargy, ataxia (unsteady gait), and dysarthria (slurred speech).[4]
• Ocular Toxicity: Infrequent but serious ocular side effects have been reported, including optic atrophy, visual disturbances, and in rare cases, blindness.[8]
• Dermatologic Effects: Alopecia (hair loss or thinning) is a common and expected side effect.[1]

Drug Interaction Profile and Clinical Management

The safe use of Lomustine requires careful consideration of potential drug-drug and drug-food interactions. These interactions can be broadly categorized as pharmacodynamic, where effects are additive, or pharmacokinetic, where the metabolism and exposure of Lomustine are altered.

Pharmacodynamic Interactions (Additive Effects)

These interactions occur when another drug enhances Lomustine's physiological effects, particularly its immunosuppression.

• Live Vaccines: The co-administration of Lomustine with live or live-attenuated vaccines is contraindicated. Due to the profound immunosuppression induced by Lomustine, administering a live vaccine (e.g., measles, mumps, rubella (MMR), varicella, rotavirus, yellow fever, intranasal influenza vaccine) can lead to uncontrolled replication of the vaccine virus, resulting in a severe, disseminated, and potentially fatal infection. Patients should avoid receiving live vaccines during Lomustine therapy and for a period of at least 3 months following its cessation to allow for immune reconstitution.[1]
• Other Myelosuppressive and Immunosuppressive Agents: Caution is required when Lomustine is used concurrently with other agents that suppress the bone marrow or the immune system. This includes other chemotherapeutic drugs, immunosuppressants used for autoimmune diseases (e.g., adalimumab, azathioprine), and novel immunotherapies like CAR-T cell products (e.g., axicabtagene ciloleucel). The combination can result in additive or synergistic myelosuppression, leading to a higher risk of severe neutropenia, thrombocytopenia, and life-threatening infections. When such combinations are necessary, clinicians must monitor blood counts with increased frequency and consider dose reductions of one or both agents.[37]

Pharmacokinetic Interactions (Altered Metabolism)

These interactions involve drugs that affect the activity of the CYP450 enzymes responsible for metabolizing Lomustine into its active and inactive forms.

• CYP450 Inhibitors: Drugs that inhibit CYP3A4, CYP2D6, or CYP2C19 can decrease the metabolism of Lomustine. This can lead to higher and more prolonged exposure to its active metabolites, thereby potentiating its toxicity, especially myelosuppression.
• Cimetidine: A well-documented example is the H2-receptor antagonist cimetidine. It is known to inhibit CYP enzymes and has been shown to potentiate the marrow toxicity of Lomustine. Concurrent use should be avoided. If an H2 blocker is required, an alternative such as famotidine or ranitidine should be chosen.[7]
• CYP450 Inducers: Drugs that induce these same CYP enzymes can accelerate the metabolism of Lomustine. This can have unpredictable effects on both efficacy and toxicity.
• Enzyme-Inducing Antiepileptic Drugs: Patients with brain tumors are often on antiepileptic medications. Strong enzyme inducers like phenytoin, carbamazepine, and phenobarbital can increase the metabolism of Lomustine. This could potentially reduce its therapeutic efficacy by clearing it from the body too quickly. Concurrent use should be avoided if possible. If unavoidable, clinicians should monitor for both reduced Lomustine efficacy and potential changes in antiepileptic drug levels.[7]

Drug-Food/Lifestyle Interactions

• Food: While there is no specific food interaction that alters the drug's pharmacology, taking Lomustine with food can increase the incidence of nausea and vomiting. Therefore, it is strongly recommended that the dose be taken on an empty stomach (at least 2 hours before or 1 hour after a meal) to minimize this common side effect.[1]
• Alcohol: Although small amounts of alcohol are not reported to have a major interaction, it is prudent for patients to avoid alcoholic beverages. Alcohol can exacerbate gastrointestinal irritation and potentially add to the risk of hepatotoxicity.[8]

Table 3: Clinically Significant Drug Interactions with Lomustine and Management Strategies
Interacting Agent/Class	Mechanism of Interaction	Potential Clinical Effect	Management Recommendation
Live or Live-Attenuated Vaccines (e.g., MMR, Varicella, Yellow Fever)	Pharmacodynamic (Additive Immunosuppression)	Risk of uncontrolled, disseminated infection from the vaccine virus.	Contraindicated. Avoid during and for at least 3 months after Lomustine therapy.
Other Myelosuppressive Agents (e.g., other chemotherapy, clozapine)	Pharmacodynamic (Additive Toxicity)	Increased severity and duration of myelosuppression; heightened risk of infection and bleeding.	Use with caution. Monitor blood counts closely; be prepared to adjust Lomustine dose based on nadir counts.
Cimetidine	Pharmacokinetic (CYP450 Inhibition)	Increased plasma concentration and duration of active Lomustine metabolites, leading to potentiated toxicity (especially myelosuppression).	Avoid concurrent use. Select an alternative H2-receptor antagonist (e.g., famotidine).
Enzyme-Inducing Antiepileptics (e.g., Phenytoin, Carbamazepine)	Pharmacokinetic (CYP450 Induction)	Accelerated metabolism of Lomustine, potentially leading to reduced therapeutic efficacy.	Avoid concurrent use if possible. If necessary, monitor closely for both Lomustine efficacy and antiepileptic drug levels.
	7

Use in Special Populations

The administration of Lomustine requires special consideration in certain patient populations due to altered physiology, increased risk of toxicity, or potential for long-term harm.

Pediatric Use

Lomustine is FDA-approved for the treatment of brain tumors and Hodgkin lymphoma in pediatric patients; however, this approval is not based on adequate and well-controlled clinical studies specifically in this population.[2] Dosing is typically calculated based on body surface area (

mg/m2), similar to adults.[1] Clinicians must exercise particular caution in children due to the risk of severe and long-term toxicities. Of paramount concern is the risk of delayed-onset pulmonary fibrosis. Reports have documented this fatal complication occurring up to 17 years after treatment with nitrosoureas in childhood, particularly in patients who also received cranial radiotherapy.[5] Long-term survivors of childhood cancer treated with these agents may experience a late reduction in pulmonary function.[45]

Geriatric Use

There are no specific clinical studies of Lomustine dedicated to patients aged 65 and over.[2] However, caution is strongly advised when prescribing for this population. Geriatric patients are more likely to have a decline in organ function, particularly renal and hepatic function, which are involved in the excretion and metabolism of Lomustine. They may also have less bone marrow reserve. Given the drug's high potential for nephrotoxicity, hepatotoxicity, and myelosuppression, dose selection for an elderly patient should be cautious, often starting at the lower end of the dosing range, with vigilant monitoring for toxicity.[2]

Pregnancy and Lactation

• Pregnancy: Lomustine is classified as FDA Pregnancy Category D, indicating positive evidence of human fetal risk.[4] Animal reproduction studies have definitively shown that Lomustine is embryotoxic and teratogenic, causing fetal abnormalities and death at doses comparable to those used in humans.[2] There are no adequate and well-controlled studies in pregnant women. Therefore, Lomustine is not recommended for use during pregnancy.
• Contraception: Due to the significant risk to a fetus, effective contraception is mandatory for patients of reproductive potential. Females should use effective birth control during treatment and for at least 2 weeks after the final dose. Males with female partners of reproductive potential must use effective contraception throughout treatment and for a period of 3.5 to 6 months after the final dose to account for the lifecycle of sperm development.[2]
• Lactation: It is unknown whether Lomustine or its active metabolites are excreted into human breast milk.[2] However, due to the potential for serious adverse reactions in a nursing infant, including myelosuppression and other toxicities, breastfeeding is not recommended during Lomustine treatment and for at least 2 weeks after the final dose is administered.[6]

Fertility

Lomustine poses a significant risk to the fertility of both male and female patients. Its cytotoxic action on rapidly dividing cells affects germ cells in the testes and ovaries. In male rats, the drug affects fertility, and in humans, it is likely to cause prolonged or permanent azoospermia (absence of sperm).[2] In women, it can lead to amenorrhea (absence of menstruation) and premature menopause.[13] Patients should be counseled about this risk before initiating therapy. For male patients, discussing options for fertility preservation, such as sperm banking, is an important part of the pre-treatment consultation.[7]

Regulatory and Commercial Landscape

The history of Lomustine is not only a story of clinical utility but also a case study in pharmaceutical economics, market dynamics, and their impact on patient care and research.

Initial Approval and Historical Context

• Lomustine was first approved by the U.S. Food and Drug Administration (FDA) in 1976.[2]
• The drug was originally developed and marketed by Bristol-Myers Squibb under the brand name CeeNU.[13]
• For decades following its approval, CeeNU was a well-established, standard-of-care chemotherapy. Its unique ability to cross the blood-brain barrier made it an indispensable tool for treating high-grade gliomas, and it was a key second-line agent for Hodgkin's lymphoma.[2]

Transition to Gleostine and Market Exclusivity

• In the years leading up to 2013, the production of CeeNU by Bristol-Myers Squibb became limited, leading to recurrent drug shortages that threatened patient care.[50]
• In 2013, NextSource Biotechnology, a specialty pharmaceutical company, acquired the manufacturing and marketing rights for the off-patent Lomustine from Bristol-Myers Squibb.[10]
• NextSource subsequently rebranded the drug as Gleostine and, in partnership with Corden Pharma, relaunched it, becoming the sole manufacturer and supplier of Lomustine in the United States.[10] A new 5 mg capsule strength was approved under the Gleostine brand in December 2014.[52]

Socioeconomic Implications: Price Increases and Access Issues

The transition to a single-source manufacturer for this old, off-patent, yet clinically vital drug created a market monopoly that has had severe socioeconomic consequences.

• Price Increases: After acquiring the rights, NextSource engaged in a strategy of aggressive and exponential price increases for Gleostine. With no approved generic alternatives available, patients, providers, and payers were forced to absorb these dramatic cost hikes.[10]
• Access Issues: The escalating cost created significant financial toxicity and barriers to access. The situation culminated in a decision in 2021 for the drug to no longer be covered by Medicare under certain circumstances, further jeopardizing access for a vulnerable patient population.[10]

The commercialization strategy for Lomustine has created a modern crisis in oncology that extends beyond the immediate financial burden on patients. This situation illustrates a critical vulnerability in the pharmaceutical market, where an old but essential off-patent drug can be acquired by a single entity, leading to a monopoly that enables price gouging. The first-order effect is the direct cost to patients and healthcare systems. The second-order effect is the creation of access barriers, as seen with the changes in insurance coverage.

However, the most insidious consequence is a third-order effect on scientific progress. Lomustine's established efficacy and predictable toxicity profile make it the standard-of-care comparator against which new drugs for brain tumors are measured in clinical trials.[10] The now-exorbitant cost and uncertain access to Gleostine have made it increasingly difficult and expensive for academic researchers and pharmaceutical companies to conduct these vital trials. This has created a significant bottleneck, with the potential to slow or even "derail progress on the development of desperately needed brain cancer drugs".[10] The commercial history of this single, decades-old medication thus casts a long shadow, threatening to impede the entire field of neuro-oncology research and development for years to come.

Conclusion and Future Perspectives

Lomustine (CCNU) stands as a paradigm of classic chemotherapy: a potent, effective agent whose clinical utility is defined by its unique pharmacology and perpetually constrained by a severe, predictable toxicity profile. Its identity as a highly lipophilic nitrosourea grants it the rare and valuable ability to penetrate the central nervous system, securing its enduring, albeit challenging, role in the armamentarium against malignant brain tumors. This report has detailed the inseparable, causal link between its mechanism of action—the induction of lethal DNA damage via alkylation and carbamoylation—and its dual identity as a therapeutic agent, a potent toxin, and a long-term carcinogen.

The pharmacokinetic profile of Lomustine, characterized by rapid conversion to active metabolites with long half-lives, directly dictates its most significant clinical feature: delayed and cumulative myelosuppression. This reality has necessitated a rigid 6-week dosing schedule and a management strategy centered on vigilant hematologic monitoring and careful dose adjustment. Despite the advent of more sophisticated targeted therapies and immunotherapies, these newer agents have yet to replicate Lomustine's reliable penetration of the blood-brain barrier. Consequently, Lomustine remains a relevant therapy, particularly for recurrent glioblastoma and as a component of combination regimens like PCV (Procarbazine, CCNU, Vincristine) for certain glioma subtypes.

Looking forward, the future of Lomustine will likely involve its continued use in combination with other agents, including temozolomide and potentially novel targeted drugs, in an effort to enhance efficacy and overcome resistance. Research may also focus on strategies to mitigate its formidable toxicities, perhaps through the development of novel drug delivery systems that could target the drug more specifically to tumor tissue or the co-administration of cytoprotective agents.

However, the story of Lomustine is also a cautionary tale. Its transition from the widely available CeeNU to the single-source, high-cost Gleostine has highlighted critical flaws in the pharmaceutical marketplace. The resulting financial toxicity and access issues have not only burdened patients but have also created a chilling effect on clinical research, impeding the development of the next generation of therapies for brain cancer. The legacy of Lomustine is therefore twofold: it is a testament to the enduring power of cytotoxic chemotherapy in treating some of our most difficult cancers, and it is a stark reminder that the challenges of drug development do not end with scientific discovery but extend deep into the complex realms of economics, regulation, and ethics.

Works cited

1. Lomustine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 2, 2025, https://www.mayoclinic.org/drugs-supplements/lomustine-oral-route/description/drg-20064559
2. Lomustine - Wikipedia, accessed August 2, 2025, https://en.wikipedia.org/wiki/Lomustine
3. CCNU - Brain Tumor | UCLA Health Jonsson Comprehensive Cancer Center, accessed August 2, 2025, https://www.uclahealth.org/cancer/cancer-services/brain-tumor/patient-resources/common-medication-information/ccnu
4. DRUG NAME: Lomustine - BC Cancer, accessed August 2, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lomustine_monograph.pdf
5. Gleostine (lomustine) Capsules - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017588s040lbl.pdf
6. Lomustine: MedlinePlus Drug Information, accessed August 2, 2025, https://medlineplus.gov/druginfo/meds/a682207.html
7. lomustine - Drug Formulary - Cancer Care Ontario, accessed August 2, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44171
8. Lomustine (CeeNU®, CCNU, Gleostine™) - Oncolink, accessed August 2, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/lomustine-ceenu-r-ccnu-gleostine
9. PRODUCT MONOGRAPH PrCeeNU* - Bristol Myers Squibb, accessed August 2, 2025, https://www.bms.com/assets/bms/ca/documents/productmonograph/CeeNU_EN_PM.pdf
10. Rogue drug maker first inflates the price of lomustine, then says No to Medicare coverage, accessed August 2, 2025, https://cancerletter.com/trials-and-tribulations/20210716_7/
11. Lomustine | C9H16ClN3O2 | CID 3950 - PubChem, accessed August 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lomustine
12. Definition of lomustine - NCI Dictionary of Cancer Terms, accessed August 2, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lomustine
13. Lomustine | 13010-47-4 - ChemicalBook, accessed August 2, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5123021.htm
14. Definition of lomustine - NCI Drug Dictionary - NCI, accessed August 2, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lomustine
15. Lomustine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB01206
16. CAS Number 13010-47-4 | Lomustine - Spectrum Chemical, accessed August 2, 2025, https://www.spectrumchemical.com/cas/13010-47-4
17. Compound: LOMUSTINE (CHEMBL514) - ChEMBL - EMBL-EBI, accessed August 2, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL514
18. Lomustine 13010-47-4 | TCI AMERICA - Tokyo Chemical Industry, accessed August 2, 2025, https://www.tcichemicals.com/MX/en/p/L0251
19. Lomustine | CAS 13010-47-4 | SCBT - Santa Cruz Biotechnology, accessed August 2, 2025, https://www.scbt.com/p/lomustine-13010-47-4
20. [Lomustine (200 mg)] - CAS [13010-47-4] - USP Store, accessed August 2, 2025, https://store.usp.org/product/1369419
21. www.cancercareontario.ca, accessed August 2, 2025, https://www.cancercareontario.ca/en/system/files_force/lomustine.pdf?download=1#:~:text=B%20%2D%20Mechanism%20of%20Action%20and,of%20DNA%20and%20RNA%20synthesis.
22. Lomustine | Cancer Care Ontario, accessed August 2, 2025, https://www.cancercareontario.ca/en/system/files_force/lomustine.pdf?download=1
23. Lomustine - NCI, accessed August 2, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/lomustine
24. Lomustine | Davis's Drug Guide for Rehabilitation Professionals, accessed August 2, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139016416
25. Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11922871/
26. Lomustine (CCNU, NCI C04740, NSC 79037, CAS Number: 13010-47-4), accessed August 2, 2025, https://www.caymanchem.com/product/21237/lomustine
27. Nitrosoureas Toxicity - StatPearls - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK599513/
28. Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications - MDPI, accessed August 2, 2025, https://www.mdpi.com/2077-0383/12/23/7442
29. Lomustine Patient Handout - BC Cancer, accessed August 2, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lomustine_handout.pdf
30. Clinical pharmacokinetics of oral CCNU (lomustine) - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/3971475/
31. Preliminary Metabolism of Lomustine in Dogs and Comparative Cytotoxicity of Lomustine and Its Major Metabolites in Canine Cells - MDPI, accessed August 2, 2025, https://www.mdpi.com/2306-7381/1/3/159
32. Pharmacokinetics of High-Dose Oral CCNU in Bone Marrow Transplant Patients - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/8765435/
33. L01AD02 - Lomustine - Acute Porphyria Drugs, accessed August 2, 2025, https://drugsporphyria.net/monograph/2957/L01AD02
34. Lomustine: Pediatric drug information, accessed August 2, 2025, https://doctorabad.com/uptodate/d/topic.htm?path=lomustine-pediatric-drug-information
35. Clinical Policy: Lomustine (Gleostine) - Superior HealthPlan, accessed August 2, 2025, https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/CP.PHAR.507-02012022.pdf
36. en.wikipedia.org, accessed August 2, 2025, https://en.wikipedia.org/wiki/Lomustine#:~:text=History-,FDA%20approval,the%20early%20twenty%2Dfirst%20century.
37. Gleostine, CCNU (lomustine) dosing, indications, interactions, adverse effects, and more, accessed August 2, 2025, https://reference.medscape.com/drug/gleostine-ccnu-lomustine-342127
38. Lomustine Completed Phase 2 Trials for Glioblastoma Multiforme (GBM) Treatment, accessed August 2, 2025, https://go.drugbank.com/drugs/DB01206/clinical_trials?conditions=DBCOND0046976&phase=2&purpose=treatment&status=completed
39. lomustine - My Cancer Genome, accessed August 2, 2025, https://www.mycancergenome.org/content/drugs/lomustine/
40. Lomustine: An Overview - ImpriMed, accessed August 2, 2025, https://www.imprimedicine.com/blog/lomustine
41. Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules - AVMA Journals, accessed August 2, 2025, https://avmajournals.avma.org/view/journals/javma/250/3/javma.250.3.322.pdf
42. Lomustine for Childhood Cancer Patients - Together by St. Jude™, accessed August 2, 2025, https://together.stjude.org/en-us/treatment-tests-procedures/medicines-list/lomustine.html
43. CeeNU® (lomustine) Capsules - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017588s037lbl.pdf
44. GLEOSTINE (lomustine) capsules, for oral use - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017588s042lbl.pdf
45. Lomustine Capsules WARNINGS - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017588s039lbl.pdf
46. Lomustine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 2, 2025, https://www.webmd.com/drugs/2/drug-8801/lomustine-oral/details
47. Lomustine Capsules: Uses & Side Effects - Cleveland Clinic, accessed August 2, 2025, https://my.clevelandclinic.org/health/drugs/19029-lomustine-ccnu-capsules
48. Lomustine - Memorial Sloan Kettering Cancer Center, accessed August 2, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/lomustine
49. S0178 Lomustine - CanMED: HCPCS - SEER - National Cancer Institute, accessed August 2, 2025, https://seer.cancer.gov/oncologytoolbox/canmed/hcpcs/S0178/
50. The Gleostine® (lomustine) brand has replaced the BMS CeeNU product, accessed August 2, 2025, https://gleostine.com/history-of-lomustine/
51. The lomustine crisis: awareness and impact of the 1500% price hike - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6303421/
52. Generic Gleostine Availability - Drugs.com, accessed August 2, 2025, https://www.drugs.com/availability/generic-gleostine.html